Charles Settle, MD
Physical Medicine & Rehabilitation · Tacoma, WANPI 1386791374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Collegium Pharmaceutical, Inc. accounts for 63.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $387 and has fallen 79.1% since, to $81 in 2023.
Across 97 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$933
- Daiichi Sankyo Inc.$181
- Orexo US, Inc.$112
- Alkermes, Inc.$51
- AbbVie$50
- Teva Pharmaceuticals USA, Inc.$41
- plus $110 from 4 others
What the payments were for
- Food & beverage$1,478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 65 | $933 |
| Daiichi Sankyo Inc. | 9 | $181 |
| Orexo US, Inc. | 6 | $112 |
| Alkermes, Inc. | 3 | $51 |
| AbbVie | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Lilly USA, LLC | 2 | $31 |
| MDD US Operations, LLC | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$1,478 in reported general payments places this provider in the 80th percentile of 260 physical medicine & rehabilitation providers in Washington.
See all physical medicine & rehabilitation providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 94 | $97,727 |
| OxycontinOxycodone Hcl | 118 | $72,943 |
| Oxymorphone Hcl ErOxymorphone Hcl | 14 | $38,881 |
| Oxycodone Hcl | 1,354 | $32,973 |
| Fentanyl | 204 | $24,117 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 627 | $19,605 |
| Morphine Sulfate ErMorphine Sulfate | 469 | $16,307 |
| MovantikNaloxegol Oxalate | 25 | $11,963 |
| Morphine Sulfate | 176 | $9,623 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 308 | $9,414 |
| Lidocaine | 81 | $9,136 |
| Gabapentin | 277 | $5,915 |
| Methadone Hcl | 188 | $3,949 |
| Buprenorphine | 16 | $3,548 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 41 | $3,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $933 | $97,72794 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 260 physical medicine & rehabilitation providers in Washington.
Other physical medicine & rehabilitation in Tacoma
- Nelson HagerTacoma$186K
- Christopher CochraneTacoma$3K
- Irfan AnsariTacoma$2K
- Mohammad SaeedTacoma$882
- Nassim RadSeattle$231K
- Martin ChildersSeattle$170K
- Theodore BrownKirkland$62K
- Angeli MayadevSeattle$51K
- Ronan CahillBellevue$22K
- Karen StanekSpokane$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.